NEW YORK, Sept. 23, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) between February 25, 2016 and August 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/keryx-biopharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing production-related difficulties in converting API to finished drug product; (2) that the issue was resulting in decreased production yields of finished drug product; (3) that, as a result, the Company would, and did exhaust its reserve of finished drug product; and (4) that, as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Keryx Biopharmaceuticals, Inc. you have until October 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



